Table 1.
Effect of exogenous cannabinoids and manipulations of the endogenous cannabinoid system on vomiting in animal models.
| Compound | Species | Dose | Emetogenic agent | Effect on emesis | Receptor mediation | References |
|---|---|---|---|---|---|---|
| Δ9-THC, THCA, AND Δ9-THC-LIKE SYNTHETICS | ||||||
| Δ9-THC | Least shrew | 20 mg/kg, i.p. | SR141716 | Reduced | CB1 | Darmani, 2001a |
| 0.25, 0.5, 1, 2.5, 5, 10 mg/kg, i.p. | Cisplatin | Reduced | Darmani, 2001b; Ray et al., 2009; Wang et al., 2009 | |||
| 5, 10 mg/kg, i.p. | D2/D3 receptor agonists | Reduced | Darmani and Crim, 2005 | |||
| Δ9-THC + tropisetron | Least shrew | 0.25, 0.5 mg/kg, i.p. | Cisplatin | Enhanced reduction | Not evaluated | Wang et al., 2009 |
| CP 55, 940 | Least shrew | 1 mg/kg, i.p. | SR141716 | Reduced | CB1 | Darmani, 2001a |
| WIN 55, 212-2 | Least shrew | 10 mg/kg, i.p. | SR141716 | Reduced | CB1 | Darmani, 2001a |
| Δ9-THC | House Musk Shrew | 3–20 mg/kg, i.p. | LiCl | Reduced | CB1 | Parker et al., 2004 |
| 2.5, 5, 10 mg/kg, i.p. | Cisplatin | Reduced | Not evaluated | Kwiatkowska et al., 2004 | ||
| Δ9-THC + ondansetron | House Musk Shrew | 1.25 mg/kg, i.p. | Cisplatin | Enhanced reduction | Not evaluated | Kwiatkowska et al., 2004 |
| Δ9-THC | Ferret | 0.5, 1 mg/kg, i.p. | Cisplatin | Reduced | CB1 | Van Sickle et al., 2003 |
| 1 mg/kg, i.p. | M6G | Reduced | Van Sickle et al., 2001 | |||
| THCA | House musk shrew | 0.05, 0.5 mg/kg, i.p | LiCl | Reduced | CB1 | Rock et al., 2013 |
| Nabilone | Dog | 0.1 mg/kg, i.v. | Cisplatin | No effect | Not evaluated | Gylys et al., 1979 |
| Cat | 0.1 mg/kg, i.v. | Apomorphine, deslanoside | Reduced | Not evaluated | London et al., 1979 | |
| 2.7 × 10−7 mole/kg, i.v. | Cisplatin | McCarthy and Borison, 1981 | ||||
| CBD AND CBDA | ||||||
| CBD | House musk shrew | 5, 10 mg/kg, i.p. or 5, 10 mg/kg, s.c. | LiCl, nicotine, cisplatin | Reduced | 5-HT1A | Kwiatkowska et al., 2004; Parker et al., 2004; Rock et al., 2012 |
| CBD | House musk shrew | 25, 40 mg/kg, i.p. | LiCl, cisplatin | Increased | Not evaluated | Kwiatkowska et al., 2004; Parker et al., 2004 |
| CBD + THC | House musk shrew | CBD (2.5 mg/kg, i.p.), THC (1 mg/kg, i.p.) | LiCl | Enhanced reduction | Not evaluated | Rock and Parker, 2015 |
| CBDA | House musk shrew | 0.1, 0.5 mg/kg, i.p. | LiCl, cisplatin | Reduced | Not evaluated | Bolognini et al., 2013 |
| CBDA + THC | House musk shrew | CBDA (0.05 mg/kg, i.p.), THC (1 mg/kg, i.p.) | LiCl | Enhanced reduction | Not evaluated | Rock and Parker, 2015 |
| AEA AND FAAH INHIBITION | ||||||
| AEA | Ferret | 1, 2 mg/kg, i.p. | M6G | Reduced | CB1 TRPV1 |
Van Sickle et al., 2005; Sharkey et al., 2007 |
| URB597 | Ferret | 3, 5 mg/kg, i.p. | M6G | Reduced | TRPV1 or CB1 | Van Sickle et al., 2005; Sharkey et al., 2007 |
| URB597 | House Musk Shrew | 0.9 mg/kg, i.p. | Cisplatin, nicotine | Reduced | CB1 | Parker et al., 2009 |
| AA-5-HT | Least shrew | 10 mg/kg, i.p. | Itself | Produced | Not evaluated | Darmani et al., 2005 |
| URB597 | 20 mg/kg, i.p. | |||||
| AA-5-HT | 2.5, 5 mg/kg | Cisplatin | No effect | Not evaluated | Darmani et al., 2005 | |
| URB597 | 5, 10 mg/kg, i.p. | |||||
| 2-AG AND MAGL INHIBITION | ||||||
| 2-AG | Least shrew | 2.5, 5, 10 mg/kg, i.p. | Itself | Produced | CB1 | Darmani, 2001c |
| 2-AG | House musk shrew | 2, 5 mg/kg, i.p. | LiCl | Reduced | Non-CB1 | Sticht et al., 2013 |
| JZL184 | House musk shrew | 16, 40 mg/kg, i.p. | LiCl | Reduced | CB1 | Sticht et al., 2013 |
| MJN110 | 10, 20 mg/kg, i.p. | CB1 | Parker et al., 2015 | |||
| 2-AG | Ferret | 1, 2 mg/kg, i.p. | M6G | Reduced | CB1 CB2 TRPV1 |
Van Sickle et al., 2005; Sharkey et al., 2007 |